Patent: 10,092,542
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,092,542
Title: | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione |
Abstract: | Stereomerically pure (+)-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoiso- indoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoin- doline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-.alpha. or the inhibition of PDE4. |
Inventor(s): | Muller; George W. (Rancho Santa Fe, CA), Schafer; Peter H. (Belle Mead, NJ), Man; Hon-Wah (Princeton, NJ), Ge; Chuansheng (Belle Mead, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 15/629,678 |
Patent Claims: | see list of patent claims |
Details for Patent 10,092,542
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Amgen, Inc. | PROLIA | denosumab | Injection | 125320 | 06/01/2010 | See Plans and Pricing | 2022-03-20 |
Amgen, Inc. | XGEVA | denosumab | Injection | 125320 | 11/18/2010 | See Plans and Pricing | 2022-03-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |